A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes.
about
Neurophysiological basis of rapid eye movement sleep behavior disorder: informing future drug developmentExpanding the Repertoire of Biomarkers for Alzheimer's Disease: Targeted and Non-targeted ApproachesThe role of biomarkers and imaging in Parkinson's disease.Diagnostic utility of CSF α-synuclein species in Parkinson's disease: protocol for a systematic review and meta-analysisCerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer's disease in a memory clinic cohort.Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer's disease.Increased CSF neurogranin concentration is specific to Alzheimer disease.Single-Molecule Imaging of Individual Amyloid Protein Aggregates in Human Biofluids.Distinct Lysosomal Network Protein Profiles in Parkinsonian Syndrome Cerebrospinal Fluid.Longitudinal Measurements of Cerebrospinal Fluid Biomarkers in Parkinson's Disease.A targeted proteomic multiplex CSF assay identifies increased malate dehydrogenase and other neurodegenerative biomarkers in individuals with Alzheimer's disease pathology.Blood-based NfL: A biomarker for differential diagnosis of parkinsonian disorderNeurochemical biomarkers in the diagnosis of frontotemporal lobar degeneration: an update.A user's guide for α-synuclein biomarker studies in biological fluids: Perianalytical considerations.Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches.The use of cerebrospinal fluid biomarkers to measure change in neurodegeneration in Alzheimer's disease clinical trials.Impairment of mitochondria dynamics by human A53T α-synuclein and rescue by NAP (davunetide) in a cell model for Parkinson's disease.Multiple system atrophy: pathogenic mechanisms and biomarkers.Cerebrospinal fluid biomarkers in Alzheimer's and Parkinson's diseases-From pathophysiology to clinical practice.Diagnostic function of the neuroinflammatory biomarker YKL-40 in Alzheimer's disease and other neurodegenerative diseases.Recent developments in circulating biomarkers in Parkinson's disease: the potential use of miRNAs in a clinical setting.Applying fluid biomarkers to Alzheimer's disease.Discovery, validation and optimization of cerebrospinal fluid biomarkers for use in Parkinson's disease.Diagnostic utility of cerebrospinal fluid α-synuclein in Parkinson's disease: A systematic review and meta-analysis.Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia.Differentiating atypical parkinsonian syndromes--a way forward?Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry.Potential clinical utility of multiple system atrophy biomarkers.Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders.Alpha-synuclein levels in patients with multiple system atrophy: a meta-analysis.Validation of soluble amyloid-β precursor protein assays as diagnostic CSF biomarkers for neurodegenerative diseases.CSF neurogranin or tau distinguish typical and atypical Alzheimer disease.Cerebrospinal fluid levels of neurofilament light chain in multiple system atrophy relative to Parkinson's disease: a meta-analysis.The Past and the Future of Alzheimer's Disease Fluid Biomarkers.Molecular biomarkers of Alzheimer's disease: progress and prospects.Plasma Biomarkers Differentiate Parkinson's Disease From Atypical Parkinsonism Syndromes.Are We Ready for Detecting α-Synuclein Prone to Aggregation in Patients? The Case of "Protein-Misfolding Cyclic Amplification" and "Real-Time Quaking-Induced Conversion" as Diagnostic Tools.Cerebrospinal fluid phosphorylated tau, visinin-like protein-1, and chitinase-3-like protein 1 in mild cognitive impairment and Alzheimer's diseaseRecent Advances in Biomarkers for Parkinson's DiseaseCerebrospinal fluid concentrations of inflammatory markers in Parkinson's disease and atypical parkinsonian disorders
P2860
Q26749275-6D4C7199-30D6-4A6B-AEF1-D07F4ACA9B66Q26770708-73F480E9-9EFA-4E9D-B8C0-F7E1651EECBCQ31041660-92E24F3C-6EDA-42FA-A31A-BF50288E06DBQ36051094-99A0C075-77BA-499E-9C0F-867824DDA4FAQ36071742-74F65F0D-522A-456A-BCB0-D5B837828001Q36454535-4CE36439-7F1C-4D23-AE03-E7C689FFF7E5Q36691986-790CB525-5A43-48CF-A839-98AA7863CFF5Q36708156-5BF618FE-0CF7-481F-BAC0-D6BA28157EAFQ37054024-EE3596E9-0CE9-421D-A1C2-39CB5AD4E0AFQ37345484-06EB6D6B-CCD4-4234-8639-FB14CC7D7238Q37648226-E278C451-DDFB-48C0-B674-B1D324FACC31Q37676938-E3617B61-6CF3-4EB9-8883-A94F98B97FA6Q38392505-C1446B8C-B70F-45C6-93C6-7DB37318CDFDQ38653383-D2A886EE-3598-466D-8A7E-0535FD8552E6Q38666247-604C5B84-C280-4175-B434-2C2A98786310Q38672062-B7E68A99-6655-43F1-A9A5-E0CD618BD075Q38730062-8FA5EBAB-02B1-446A-9714-EDCB5BF5CE19Q38813304-6B93CA19-73E3-4D44-A9ED-906981C06E48Q38825497-331AAC15-C87B-4E60-988E-1E7EA947B45AQ38915171-4B2238F6-3F40-4A07-9F7A-E3E406696192Q39010887-066A374F-AB99-4704-A68C-8D5C93644518Q39251035-9675615E-B232-4997-B522-9F7A83366F64Q39366291-A3259C1D-1A65-456F-B468-84587F4FEA20Q40053985-26C725FE-BFFA-43D5-BF77-CDA4613401D4Q41163005-30B7BE45-9E8B-4DBD-B7B9-B1DFB2AAC748Q42432396-2CFA2767-F175-4E29-9276-80DDFBE0748AQ47587631-F0B9BC2A-C231-44BC-9DD3-0B4A6B36866AQ47663712-9FCE5C13-8DF1-4A41-9E30-C02274AA542FQ47708649-58C4EB58-423A-4FAD-B245-EE90B2B07214Q47754301-BBCF52CC-8AE7-489F-A469-C379288177CAQ48887740-4E135311-9692-4A96-A0AC-6CAB0541A633Q50233550-9CEFFD5A-2A72-43FA-9621-6D1BA6EE0BDEQ51298413-54EDF081-D137-4F1B-81E7-2594AD8648B8Q52644601-8266456C-A6F5-4BC5-B860-E8DCC50B80C2Q54946040-467D3C83-E83A-49D1-8E86-27EBC2394032Q55110559-77E365D8-42C1-4E18-9979-7B223B32DE33Q55307741-682FE62F-A60D-447F-8710-29EB9DCF63E3Q57493750-89412E45-38D6-4A67-8596-6B137DEE3CC6Q58572579-B49A3D44-E973-43DA-BB2E-71118BFE9F16Q58763366-C3EF71D2-EE21-4221-B63A-778022324341
P2860
A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
A panel of nine cerebrospinal ...... ypical parkinsonian syndromes.
@ast
A panel of nine cerebrospinal ...... ypical parkinsonian syndromes.
@en
type
label
A panel of nine cerebrospinal ...... ypical parkinsonian syndromes.
@ast
A panel of nine cerebrospinal ...... ypical parkinsonian syndromes.
@en
prefLabel
A panel of nine cerebrospinal ...... ypical parkinsonian syndromes.
@ast
A panel of nine cerebrospinal ...... ypical parkinsonian syndromes.
@en
P2093
P2860
P50
P921
P356
P1476
A panel of nine cerebrospinal ...... ypical parkinsonian syndromes.
@en
P2093
H R Morris
J M Schott
N K Magdalinou
R W Paterson
R de Silva
T T Warner
P2860
P304
P356
10.1136/JNNP-2014-309562
P407
P577
2015-01-14T00:00:00Z